Related Experiment Video

Updated: Apr 12, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.2K

Possible FDA-approved drugs to treat Ebola virus infection

Shu Yuan1

  • 1College of Resources Science and Technology, Sichuan Agricultural University, Chengdu, 611130 China.

Infectious Diseases of Poverty
|May 19, 2015
PubMed

Insights

This study proposes a novel hypothetical treatment for Ebola virus (EBOV) infection using Miglustat and Toremifene. This combination aims to synergistically inhibit viral replication and improve patient outcomes.

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Ebola virus infection (EBOV) currently lacks effective treatments, with many experimental drugs and vaccines awaiting human trials.
  • Existing FDA-approved drugs like Gleevec and Tasigna show limited efficacy against EBOV at clinical dosages.
  • Miglustat inhibits EBOV assembly and secretion, while Clomiphene and Toremifene prevent viral membrane fusion, improving survival in mice.

Purpose of the Study:

  • To propose a hypothetical synergistic treatment protocol for EBOV infection.
  • To investigate the combined therapeutic potential of Miglustat and Toremifene against EBOV.
  • To address the limitations of current EBOV treatment strategies.

Main Methods:

  • Literature review of existing EBOV treatments and drug mechanisms.
  • Hypothetical combination therapy design integrating Miglustat and Toremifene.
  • Consideration of supportive treatments for EBOV-induced complications like DIC.

Main Results:

  • Miglustat inhibits EBOV particle assembly and secretion.
  • Toremifene prevents EBOV membrane fusion, demonstrating significant survival rates in treated mice.
  • A synergistic effect is hypothesized when combining Miglustat and Toremifene.

Conclusions:

  • A combined Miglustat and Toremifene treatment protocol offers a promising hypothetical strategy for synergistic EBOV inhibition.
  • Further research and clinical trials are warranted to validate this proposed treatment.
  • Supportive care, including blood transfusions and DIC management, remains crucial for EBOV patients.
Keywords:
Disseminated intravascular coagulationEbola virus infectionGlycosylation inhibitorsMiglustatNiemann-Pick C1 inhibitorsToremifene

More Related Videos

Rapid, Safe, and Simple Manual Bedside Nucleic Acid Extraction for the Detection of Virus in Whole Blood Samples06:59

Rapid, Safe, and Simple Manual Bedside Nucleic Acid Extraction for the Detection of Virus in Whole Blood Samples

Published on: June 30, 2018

7.9K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.7K

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
34.0K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
332
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
85
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
924
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K